Communiqué from the Extraordinary General Meeting of Alzinova AB on 27 February 2020

Today, 27 February 2020, Alzinova AB (publ) held an Extraordinary General Meeting. The General Meeting passed the following resolutions regarding the number of board members of the Company and the appointment of a new board member.

The Extraordinary General Meeting resolved that the Board of Directors shall comprise five members up until the end of the next Annual General Meeting. The existing board members Björn Larsson, Clas Malmeström, Carol Routledge and Anders Waas will remain on the board with Björn Larsson as Chairman for the period up until the end of the next Annual General Meeting. The Extraordinary General Meeting further resolved to elect Pernilla Sandwall as new member of the board for the period up until the end of the next Annual General Meeting. The Company thereby broadens its competences and the composition of the board.

"We are very happy to welcome Pernilla as new board member of Alzinova AB. With her experience, Pernilla will add valuable skills to the board as the Company now moves into a clinical development phase," says Björn Larsson, Chairman of the Board.

 

For more information, please contact:

Kristina Torfgård, CEO

Telephone: +46 70 846 79 75

E-mail: kristina.torfgard@alzinova.com

Certified Adviser:

Corpura Fondkommission AB

E-mail: ca@corpura.se

Telephone: 0768-532822

Home page: www.corpura.se

About Alzinova AB  

Alzinova AB is engaged in pharmaceutical research and development for treatment of Alzheimer’s disease – one of our major health scourges, without efficient treatment options. The Company's patented technology enables the development of novel therapies, that with high precision could target the substances involved in the formation of the disease and render them harmless. Alzinova's focus is to develop a vaccine as a long-acting therapy for treatment and prevention of Alzheimer's disease. The vaccine is under preclinical development, in preparation for human clinical trials. Alzinova was founded by researchers from the MIVAC research center at the University of Gothenburg, and by GU Ventures AB.

Om oss

Alzinova AB bedriver forskning och utveckling av läkemedel för behandling av Alzheimers sjukdom. Bolagets patenterade teknologi möjliggör utveckling av nya terapier med potential att med stor träffsäkerhet angripa de skadliga ämnen som är centrala för sjukdomens uppkomst. Alzinovas fokus är utveckling av ett vaccin som ett långverkande och kostnadseffektivt läkemedel för behandling och förebyggande av Alzheimers sjukdom.

Prenumerera

Dokument & länkar